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Women with rheumatoid arthritis (RA) are often of childbearing age and therefore questions 
regarding reproductive health and the use of medications including disease modifying anti-
rheumatic drugs (DMARDs) may arise during the clinical consultation. Each patient requires 
individual assessment in order to effectively manage the disease while minimizing any 
treatment-associated risks to the fetus.  Although good-quality controlled trials are lacking, 
there is an increasing volume of evidence surrounding the use of immunosuppressive 
therapies in pregnancy and lactation.  This review summarises the currently available 
information which can be of benefit to clinicians guiding patients and their families through 
the risks and benefits of continuing RA therapy during pregnancy and lactation. Further 
studies and ongoing surveillance of drug safety in pregnancy are required to resolve the 














Rheumatoid arthritis (RA) has a prevalence of approximately 0.5-1%,, although this varies 
according to geography, with a female:male ratio of 2:1 to 3:1(1). Pregnancy in the patient 
with RA is therefore a clinical scenario that is not uncommon, however management is 
complicated by limited safety data for the commonly used anti-rheumatic drugs. In Australia, 
the Therapeutic Goods Administration (TGA) pregnancy classification is used to categorise 
drugs in pregnancy (Table 1). It is important to note that these categories are not hierarchical 
(ie. assignment of category B does not imply greater safety than category C) and relate to the 
level of evidence available for a particular drug. Other potential issues with this system are 
that it does not take into account the route of administration or stage of pregnancy at which a 
drug is used(2). Furthermore, the clinical context in which a drug is used must be taken into 
consideration, particularly if cessation of therapy will lead to harm from untreated disease. A 
similar classification system established by the Food and Drug Authority has been in use in 
the United States, but is currently being phased out in favour of more detailed descriptions of 
risk.  
Many factors account for the paucity of drug safety data in pregnancy, the most important 
being the deliberate exclusion of pregnant women from drug trials. Most data are, therefore, 
derived from case reports, post-marketing surveillance and large registries, all of which 
provide a considerably weaker level of evidence. Additionally, patients in these studies are 
often taking multiple medications so it is difficult to attribute observed fetal abnormalities to 
a particular drug. Safety data are often extrapolated from other conditions, such as 
inflammatory bowel disease (IBD), however it is unclear how applicable the findings are to 
RA patients, particularly when dosing regimens differ.  
 
Several new therapies have become available to RA patients over the last decade, in 
particular the biologic disease modifying anti-rheumatic drugs (bDMARDs).  There is little 
 
 
long-term follow-up data for these drugs at this stage, however increasing numbers of 
patients are being treated and so ongoing observational data will be forthcoming. Guidelines 
will need to be updated regularly as more evidence becomes available. Helpful local 
resources for Australian clinicians include the Australian Rheumatology Association 
Prescriber’s Information on Medications for Rheumatic Diseases in Pregnancy 
(http://rheumatology.org.au/community/PatientMedicineInformation.asp). Other regularly 
updated online resources are MotherToBaby (www.mothertobaby.org/), a service of the 
Organization of Teratology Information Specialists, and LactMed 
(http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm), run by the US National Library of 
Medicine. 
 
In this review (and Table 2) we summarise the currently available evidence for the safety of 
nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, synthetic disease 
modifying anti-rheumatic drugs (DMARDs) and bDMARDs in pregnancy and lactation. We 
reference the TGA categories, as although an imperfect system, they are in common use and 





Although a general management principle in RA is to discontinue NSAIDs once disease 
activity is adequately controlled with DMARD therapy, a significant proportion of patients 
remain on NSAIDs for pain relief. Non-selective NSAIDs are classified as category C drugs 
in pregnancy. Given that animal and human studies have shown inhibition of ovulation and 
animal studies inhibition of embryo implantation with NSAID use(3), it is usually 
 
 
recommended that they are ceased at the beginning of a conception cycle and recommenced 
once pregnancy is confirmed(4). Several studies have shown an increased risk of spontaneous 
abortion with NSAIDs(5-7), particularly around the time of conception, however the 
contribution of the underlying indication for the NSAID is unknown. Although another large 
study has shown no association with spontaneous abortion(8), it is generally considered 
prudent to limit NSAID use during the first trimester.  
 
Despite several case-control studies suggesting an association between NSAID use in early 
pregnancy and gastroschisis and cardiac malformations(9), large population-based studies 
have found no conclusive evidence that non-selective NSAIDs are teratogenic in humans(4). 
Renal failure and coagulopathy have been reported with proglonged, high-dose NSAID use 
later in pregnancy(10). Data regarding the safety of cyclooxygenase (COX)-2 inhibitors are 
limited, although one study of 114 women exposed to COX-2 inhibitors in pregnancy showed 
an increase in musculoskeletal malformations compared with controls(11). Given the lack of 
data in this area, COX-2 inhibitors should continue to be avoided in pregnancy.  
 
Because COX-1 and COX-2 are expressed in the endothelium and smooth muscle of the 
ductus arteriosus, all NSAIDs can lead to premature closure of the ductus arteriosus in the 
third trimester(9) and should be ceased prior to 30 weeks’ gestation.  
 
Corticosteroids 
Like NSAIDs, corticosteroids are best considered an adjunct for temporary disease control 
but in clinical practice these drugs are still used by a substantial number of RA patients. The 
non-fluorinated corticosteroids prednisolone and prednisone, both classified as category A 
drugs, are 90% metabolised by the enzyme placental dehydrogenase, leaving 10% of drug to 
 
 
reach the fetus(3). The fluorinated corticosteroids betamethasone and dexamethasone are not 
metabolised by placental dehydrogenase, however, and are the drugs of choice when the fetus 
rather than the mother is the target of therapy. Animal studies have shown an association 
between glucocorticoids and cleft palate, cataracts, fetal loss and fetal growth restriction(12, 
13). Despite disparate results from several human studies(3), a meta-analysis of case-control 
studies examining exposure to corticosteroids in the first trimester suggested an odds ratio 
(OR) of 3.35 for oral clefts, indicating a three-fold increase in risk(14). A 2014 population-
based study, however, found no association between corticosteroid use and oral clefts(15). 
There is no evidence of any other congenital abnormalities with corticosteroid exposure in 
humans. Given the potential risk of oral clefts, it is preferable to minimise glucocorticoid 
dose in the first trimester of pregnancy.  
 
Corticosteroid use later in pregnancy is associated with gestational diabetes mellitus, 
pregnancy-induced hypertension, premature rupture of membranes and intrauterine growth 
restriction, so doses are best minimised during the third trimester(4). If intra-articular 
injections are required, the non-fluorinated methylprednisolone is the preferred agent as 






Sulfasalazine (SSZ) is used alone or as part of combination therapy in RA, but is also 
prescribed extensively in IBD, and much of its pregnancy safety data come from this setting. 
As no fetal harm has been demonstrated with SSZ in animal studies and it is generally 
 
 
considered safe in pregnancy, it is classified as a category A drug. Although there are case 
reports of congenital malformations with SSZ exposure(9), these were not confirmed in 
larger population-based studies(16) or a 2008 meta-analysis(17). There is a case report of 
reversible congenital neutropenia following maternal SSZ at a dose of 3 g daily(18), so it is 
recommended that doses should not exceed 2 g daily. As SSZ is a folate antagonist, folate 
supplementation should be taken pre-conception and throughout pregnancy. 
 
In males, the sulfapyridine component of SSZ is well-recognised to impede spermatogenesis 
and reduce sperm motility and quality(19). These changes are reversible so it is 




Hydroxychloroquine (HCQ) is an anti-malarial with immunomodulatory activity used as 
monotherapy or in combination therapy for RA. Despite theoretical concerns of retinal 
toxicity and ototoxicity extrapolated from the use of chloroquine in pregnancy, multiple 
human studies in patients with connective tissue diseases (including two large controlled 
studies(20, 21)) have shown no increased risk of congenital abnormalities with HCQ 
exposure. There are few studies addressing the safety of HCQ in RA. In clinical practice 
HCQ is therefore considered safe in pregnancy in the patient with RA, but because of the lack 
of data it is classified as a category D drug.  
 
Methotrexate 
Methotrexate (MTX), the methyl derivative of amniopterin, is a folate antagonist that inhibits 
dihydrofolate reductase and has long formed the backbone of therapy in most patients with 
 
 
moderate to severe RA. MTX is embryotoxic and teratogenic in both animals and humans 
and high-dose use in pregnancy is associated with the amniopterin/MTX syndrome, features 
of which include cranial-facial abnormalities, limb foreshortening, growth deficiency and 
developmental delay/mental retardation(22). MTX is therefore classified as a category D 
drug and its use in pregnancy is contra-indicated. 
 
Much of the literature regarding the teratogenicity of MTX stems from its high-dose use as a 
chemotherapy agent in malignancy. The prevalence of congenital abnormalities with low 
dose weekly MTX exposure (5 to 25 mg/week) in RA is less clear(3). A 2014 prospective 
multi-centre cohort study of 188 pregnancies exposed to low-dose weekly MTX found an 
increased risk of spontaneous abortion (adjusted OR 2.2, 95% CI 1.3-3.2) and major birth 
defects (adjusted OR 3.1, 95% CI 1.0-9.5) compared to women without autoimmune 
disease(23). None of the abnormalities seen, however, were definite examples of MTX 
embryopathy. A 2009 review of low-dose weekly MTX in 101 RA patients found that 
spontaneous abortion occurred in 19 (18%) pregnancies, and congenital malformations in 5 
(9%) of 55 live births(24). The risk of congenital abnormalities is thought to be highest with 
MTX exposure at six to eight weeks gestation at doses of 10 mg weekly or higher, although 
this is based on limited data(25). 
 
Given that MTX accumulates in cells and can leach out of tissues for several weeks, it is 
recommended that this drug be ceased at least three months prior to conception. Folic acid 
supplementation should be continued throughout the pre-conception period and first trimester 
of pregnancy. Although there are no reports of teratogenicity in the offspring of males on 






Leflunomide (LEF) is a pyrimidine antagonist with antiproliferative activity used in moderate 
to severe RA. Despite limited experience in human pregnancies, LEF is classified as a 
category X drug given theoretical risks extrapolated from its mechanism of action and animal 
studies that have shown it to be both embryotoxic and teratogenic. Abnormalities observed in 
animals include growth retardation and cranial, ophthalmic, skeletal and cardiac 
abnormalities(27, 28). 
 
As the active metabolite of LEF is detectable in plasma for up to two years following drug 
cessation, women planning to conceive should undergo a cholestyramine washout using 
cholestyramine 8g three times daily for 11 days. Plasma LEF concentration should then be 
measured and must be <0.02mg/L on two occasions at least 14 days apart. The manufacturer 
recommends this procedure also be followed in men, although there is no evidence of 
abnormalities in the offspring of men taking LEF. 
 
There is one case report of right eye blindness and cerebral palsy in an infant born 
prematurely after LEF exposure during the first 21 weeks of gestation prior to cholestyramine 
washout, although causality could not be determined(29). A prospective cohort study of 64 
women with RA who received LEF during the first trimester and underwent cholestyramine 
washout revealed no difference in major structural defects, compared with 108 controls with 
RA who were not treated with LEF and 78 healthy controls(30). An extension of this study 
reported outcomes in an additional 45 women exposed to LEF during or in the two years 
prior to pregnancy(31). There were two (12.5%) major structural defects in the 16 women 
who had first trimester LEF exposure but none in the 29 who were exposed prior to 
 
 
conception. The authors concluded that there is too little evidence to draw firm conclusions, 
however, the 12.5% rate of abnormalities is four times the background rate of 3% in the 
general population. 
 
If an unplanned pregnancy does occur in the setting of exposure to MTX or LEF, they should 
be ceased immediately and the patient referred to a genetics counsellor and maternal-fetal 
medicine specialist for discussion of risk and further management. Additionally, patients on 
LEF should undergo a cholestyramine washout. 
 
Biologic DMARDs 
Biological DMARDS are parenterally administered antibodies which are, in Australia, 
reserved for the treatment of patients with severe RA that is refractory to standard DMARD 
therapy. As these drugs are relatively new, studies of analogous monoclonal antibodies in 
animals are limited, as are human safety data. Most of the human data come from large drug 
registries (including those maintained by manufacturers) and the IBD literature, where 
tumour-necrosis-factor (TNF)-inhibitor use in pregnancy is more prevalent given the clear 
association of increased IBD activity with poor pregnancy outcomes(32). Because there is 
active transport of IgG maternal antibodies across the placenta during the second and third 
trimesters, biologics possessing the Fc portion of the immunoglobulin molecule will be 
transported into the fetal circulation from the second trimester onwards, with levels 
increasing throughout pregnancy and even exceeding maternal concentrations if continued 
until birth(33). Currently all biologics are classified as category C in pregnancy except for 






TNF-inhibitors are the best studied of the biologics. Infliximab is a chimeric monoclonal 
antibody, etanercept is a soluble receptor inhibitor and adalimumab, golimumab and 
certolizumab are humanised antibodies to TNF. Because etanercept is a fusion protein, there 
is less transplacental passage than of complete antibodies(34). Certolizumab lacks an Fc 
component and thus cannot be actively transported across the placenta(35). There was initial 
concern stemming from a 2009 uncontrolled study of voluntarily reported events that 
infliximab and etanercept were associated with the VACTERL spectrum of anomalies 
(vertebral abnormalities, anal atresia, cardiac defects, tracheo-oesophageal, renal and limb 
abnormalities)(36). Multiple subsequent studies have not confirmed this association, nor any 
increased risk of congenital anomalies(37-40). Other concerns about TNF inhibitors and 
other biologics relate to the potential immunosuppressive effect on the infant after birth. 
There is a single case report of death from disseminated BCG following BCG vaccination of 
a three-month-old infant who was exposed to infliximab throughout his mother’s 
pregnancy(41). It is therefore recommended that administration of live vaccines (BCG, 
rotavirus, varicella and measles, mumps, rubella) is postponed until the infant is six months 
of age if there has been TNF-inhibitor exposure during pregnancy. Because very little TNF-
inhibitor passes into the fetal circulation during the first trimester, it is currently considered 
low risk to continue therapy throughout the peri-conception period and at least until 
pregnancy is confirmed. In individual cases of severe maternal disease, TNF-inhibitors have 
been continued until the start of the third trimester, although studies of long-term outcome in 
children following exposure during pregnancy are lacking. Given that smaller amounts of 
certolizumab pass into the fetal circulation, it may have a theoretical safety advantage over 





Rituximab is a monoclonal antibody directed against CD20 on B cells. The largest report of 
rituximab in pregnancy identified 231 patients, with RA the indication for therapy in 41 
patients(42). There was concomitant exposure to teratogenic medications in over 50% of 
patients, most commonly MTX but also combination chemotherapy. Of the 153 pregnancies 
with known outcome there were 90 live births, 22 of which were premature, and one neonatal 
death at six weeks. Haematologic abnormalities were present in 11 neonates and infection in 
four, none of whom had haematologic abnormalities. Two congenital malformations were 
reported. Although no worrying signals were identified in this study, given the lack of 
population-based, prospective data and the long half-life of rituximab, women are 
recommended to avoid pregnancy for 12 months following rituximab infusion. 
 
Abatacept 
Abatacept is a cytotoxic T-lymphocyte antigen (CTLA)-4 immunoglobulin fusion protein 
that blocks co-stimulation of T-cells by antigen presenting cells. There is a single case report 
of a healthy baby born at term to a mother with RA who was administered abatacept at 2.5 
weeks gestation and also continued MTX until the pregnancy was confirmed(43). Eight other 
pregnancies have been reported in RA patients after abatacept exposure, seven of whom were 
on concomitant MTX and one on LEF(44).  Spontaneous abortion occurred in three patients, 
two of whom had a past history of spontaneous abortion, and two had elective terminations. 
Given the lack of information, abatacept is not recommended in pregnant patients and it is 






Tocilizumab is a humanised interleukin (IL)-6 receptor antibody. In the largest report of 
tocilizumab exposure in pregnancy(45), 33 pregnancies were reported in 32 patients from 
eight tocilizumab trials. Twenty-six patients were on concomitant MTX. Thirteen 
pregnancies were electively terminated and there were seven spontaneous abortions. Of the 
11 deliveries, 10 were healthy and one infant died of acute respiratory distress syndrome 
three days after emergency caesarean section for intrapartum fetomaternal haemorrhage. A 
further six pregnancies were reported from a Japanese biologics registry(46). There was one 
spontaneous abortion and five healthy births at full term with no congenital anomalies. Given 
the paucity of data, pregnancy is not recommended for patients on tocilizumab and a period 
of three months after the last infusion is generally recommended before attempting 
conception.  
 
Drug safety in lactation 
The benefits of breastfeeding to both mother and infant are well documented. The National 
Health and Medical Research Council recommend that infants are exclusively breastfed to 
around six months of age, with continuation to 12 months and beyond for as long as mother 
and child desire. Postpartum flare as well as existing joint damage may complicate 
breastfeeding in women with RA. Whilst some drugs are safe in lactation, others are not and 
if instituted require cessation of breastfeeding. Many women find this a difficult decision to 
make and may need to be reassured by their educated health practitioners that control of their 
RA is important to limit further joint damage. Ultimately this is a decision to be made on a 
case-by-case basis by the patient and their clinician with full discussion of risks and benefits 




Drugs diffuse into breastmilk in differing amounts depending on their physical properties and 
pharmacokinetics(47). Recommendations regarding drug safety are made based on 
theoretical concerns, measured drug levels in breastmilk and infant serum, and case reports 
(47). Short-term administration of NSAIDs is generally considered low risk(48), with short-
acting NSAIDs such as ibuprofen preferred(49). Given their anti-platelet effect they should 
be avoided if there is thrombocytopenia in the infant. Doses should be administered just after 
breastfeeding in order to minimise infant exposure at the next feed. Prednisolone is also 
considered safe in breastfeeding, with several reports suggesting no adverse effects in 
children breastfed during long-term use(49). Delaying feeding for four hours after a dose is 
recommended to minimise infant exposure(49). 
 
In terms of synthetic DMARDs, HCQ and SSZ are considered safe in breastfeeding whilst 
MTX and LEF are not. Exposure to HCQ through breastmilk has not been demonstrated to 
have any long-term effect on visual function or neurodevelopmental outcomes(50). There is a 
single case report of bloody diarrhoea in a two-month-old infant exposed to SSZ through 
breastfeeding, with resolution upon cessation of the mother’s dose of 3g/day(51).  SSZ 
exposure should be avoided in infants who are premature, have hyperbilirubinaemia or 
glucose-6-phosphate dehydrogenase deficiency given that its metabolites can displace 
bilirubin and cause neonatal jaundice(52). Therefore, SSZ is considered safe in full-term 
infants provided they are monitored closely for adverse events. 
 
Neither MTX nor LEF are compatible with breastfeeding. As MTX is excreted into 
breastmilk in very low concentrations(53) it is unknown whether the once-weekly doses used 
in RA pose any risk to infant safety. Given theoretical concerns about accumulation in infant 
tissues, immunosuppression and adverse effects on growth, however, it is not recommended. 
 
 
Likewise there are no published data regarding safety of LEF in lactation but given 
theoretical risks to the infant and its long half-life, its use is not recommended.  
 
Although there are limited data regarding the safety of TNF-inhibitors in lactation, the 
theoretical risk of harm to the infant is low given the poor diffusion of high molecular weight 
proteins into breastmilk and anticipated minimal absorption by the infant due to destruction 
of the drug in the gastrointestinal tract. Infliximab, adalimumab and etanercept have all been 
demonstrated to be excreted into breastmilk in small amounts(47). Certolizumab was 
undetectable in breastmilk in a single case report of its use in breastfeeding(33) and there are 
no data on golimumab. If a decision is made to use TNF-inhibitors during breastfeeding, 
informed patient consent is required and the infant should be monitored for possible side 
effects. There is still no information regarding rituximab, abatacept or tocilizumab in 
breastfeeding so they are best avoided. 
 
Conclusion 
Preconception counseling including review of medications is crucial in young women with 
RA.  Maintaining low disease activity prior to conception and throughout pregnancy and 
breastfeeding will result in better outcomes for mother and baby.  Although good-quality 
controlled trials are lacking, the currently available data presented in this review is of benefit 
when guiding patients and their families through the risks and benefits of continuing RA 
therapy. Further studies and ongoing surveillance of drug safety in pregnancy are required to 
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